A Phase I, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Adult Patients With Wild-type TP53 Enriched Advanced Solid Tumors and Expansion in Patients With MDM2 Amplified Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2018
At a glance
- Drugs BI 907828 (Primary)
- Indications Brain metastases; Glioblastoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 06 Jun 2018 Planned End Date changed from 24 Apr 2023 to 13 Jun 2023.
- 06 Jun 2018 Status changed from not yet recruiting to recruiting.
- 15 May 2018 Planned End Date changed from 16 Aug 2023 to 24 Apr 2023.